Cost–Effectiveness of Combinatorial Pharmacogenomic Testing for Depression from the Canadian Public Payer Perspective

Authors:

Abstract
Aim: Evaluate cost–effectiveness of combinatorial pharmacogenomic (PGx) testing, versus treatment as usual (TAU), to guide treatment for patients with depression, from the Canadian public healthcar...
Funding Information
  • Assurex Health

This publication has 16 references indexed in Scilit: